SCLERO.ORG is retiring 4-24-2021. Thank you for the memories! You'll still find us in the Wayback Machine, and we'll carry your stories in our hearts forever.
Scleroderma Newsroom
ISN News Manager: Jo Frowde
Media Stories
Scleroderma Archive
We maintain news archives for the most recent 3 years.
2018: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
2021 - 2020 - 2019 - 2018

October 2018 Scleroderma News

Corbus Pharmaceuticals Expands Target Indications by Adding More Than 600 Compounds Focused on the Endocannabinoid System from Jenrin Discovery. Corbus Pharmaceuticals Holdings, Inc. announced today that it has licensed the exclusive worldwide rights to develop, manufacture and market drug candidates, which includes CRB-4001, a peripherally–restricted, CB1 inverse agonist targeting liver, lung, heart and kidney fibrotic diseases. Corbus Pharmaceuticals, 09/20/2018. (Also see Clinical Trials and Endocannabinoid System)

High–frequency ultrasound (HFU) of the skin in systemic sclerosis (SSc): an exploratory study to examine correlation with disease activity and to define the minimally detectable difference. In the study, HFU was able to measure skin thickness, it correlated quantitatively with a valid measure of SSc activity, and a minimal detectable difference was identified. PubMed, Arthritis Res Ther, 2018 Aug 16;20(1):181. (Also see Skin Fibrosis)

Serum biomarker for diagnostic evaluation of pulmonary arterial hypertension in systemic sclerosis (SSc–PAH). The combination of Midkine and Follistatin-like 3 can serve as an SSc–PAH biomarker and are potential drug targets for this rare disease population. PubMed, Arthritis Res Ther, 2018 Aug 16;20(1):185. (Also see Pulmonary Hypertension Diagnosis)

Characteristics and Outcomes of Patients With Systemic Sclerosis (Scleroderma) Requiring Renal Replacement Therapy in Europe. Patients with scleroderma had a higher rate of recovery from renal replacement therapy dependence than controls. PubMed, Am J Kidney Dis, 08/16/2018. (Also see Kidney (Renal) Dialysis and Transplant)

An orally–active adiponectin receptor agonist mitigates cutaneous fibrosis, inflammation and microvascular pathology in a murine model of systemic sclerosis (SSc). In vitro, AdipoRon abrogated profibrotic responses elicited by TGF-ß in normal fibroblasts, and reversed the inherently–activated profibrotic phenotype of SSc fibroblasts. PubMed, Sci Rep, 2018 Aug 7;8(1):11843. (Also see Fibroblasts)

FDA Grants Fast Track Status to Fibrocell's Gene Therapy FCX-013 for Localized Scleroderma. Fibrocell Science's gene therapy candidate FCX-013 received fast track designation by the U.S. Food and Drug Administration as a treatment for moderate––to–severe localized scleroderma. Scleroderma News, 09/06/2018. (Also see Clinical Trials)

Evolving symptoms of Raynaud's phenomenon (RP) in systemic sclerosis (SSc) are associated with physician and patient–reported assessments of disease severity. Patients identify with distinct patterns of SSc–RP that may relate to progression of the obliterative microangiopathy of SSc. PubMed, Arthritis Care Res (Hoboken), 08/21/2018. (Also see Raynaud's Phenomenon)

A randomised placebo–controlled double–blind trial to assess the safety of intramuscular administration of allogeneic mesenchymal stromal cells (MSCs) for digital ulcers (DUs) in systemic sclerosis (SSc). The Mesenchymal stromal cells for Angiogenesis and Neovascularization in digital Ulcers of Systemic Sclerosis (MANUS) Trial intended to assess the safety and potential efficacy of MSCs for DUs of SSc. PubMed, BMJ Open, 2018 Aug 20;8(8):e020479. (Also see Treatments for Digital Ulcers)

Hand and wrist joint procedures in patients with scleroderma: a systematic review. The application of joint procedures in scleroderma hands and wrists seems to be associated with low morbidity. PubMed, J Hand Surg Eur Vol, 2018 Sep 3:1753193418795632. (Also see Hand and Joint Involvement)

Immune complexes (ICs) containing scleroderma (SSc)–specific autoantibodies induce a profibrotic and proinflammatory phenotype in skin fibroblasts. These data provide the first demonstration of the proinflammatory and profibrotic effects of SSc–ICs on fibroblasts, suggesting the potential pathogenicity of SSc autoantibodies. PubMed, Arthritis Res Ther, 2018 Aug 29;20(1):187. (Also see Fibroblasts and Antibodies in Systemic Scleroderma)

Go to Scleroderma Medical News: September 2018

SCLERO.ORG was the world's leading nonprofit for trustworthy research, support, education and awareness for scleroderma and related illnesses from 1998 to 2021. It was a grassroots movement from the original Scleroderma from A to Z web site, which was founded by Shelley Ensz. We were a 501(c)(3) U.S.-based public charitable foundation. We closed this web site and our nonprofit agency in April 2021.

International Scleroderma Network (ISN)